text:
Journal of Nanomaterials
Journal of Nanomaterials / 2020 / Article
AbstractIntroductionMaterials and MethodsResultsDiscussionConclusionData AvailabilityConflicts of InterestAuthors' ContributionsAcknowledgmentsReferencesCopyright
Applications of Nanobiomaterials in Tissue Repair
View this Special Issue
Xianling Feng, Xinxin Yue, Mao Niu, "Simvastatin-Loaded Nanomicelles Enhance the Osteogenic Effect of Simvastatin", Journal of Nanomaterials, vol. 2020, Article ID 1072765, 14 pages, 2020. https://doi.org/10.1155/2020/1072765
Simvastatin-Loaded Nanomicelles Enhance the Osteogenic Effect of Simvastatin
Xianling Feng ,1 Xinxin Yue ,2 and Mao Niu 3
1School of Medicine, Shenzhen University, Shenzhen 518060, China
2Department of Dental Implantology, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Beijing 100050, China
3School of Medical Technology and Nursing, Shenzhen Polytechnic, Shenzhen 518055, China
Academic Editor: Xiaoming Li
Received26 Jun 2020
Revised30 Oct 2020
Accepted05 Nov 2020
Published19 Nov 2020
Objectives. The present study intended to further verify that simvastatin-loaded nanomicelles (SVNs) enhanced the role of simvastatin (SV) in promoting osteoblast differentiation in vitro and to evaluate the effect of SVNs on bone defect repair in vivo. Methods. SVNs were synthesized by dialysis. MG63 cells were subjected to intervention with 0.25 μmol/l of SVNs and SV. A 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay kit and flow cytometry were used to determine cell proliferation activity, cell cycle distribution, and apoptosis. The osteoblastic differentiation of MG 63 cells was evaluated by measuring alkaline phosphatase (ALP) activity, ALP staining, and the expression levels of the osterix (Osx) and osteocalcin (OC) proteins. In addition, 0.5 mg of SVNs or SV was applied to the skull defect area of rabbits. Micro-CT, hematoxylin and eosin (HE) staining, and Masson's trichrome staining were used for qualitative and quantitative evaluation of new bone in three dimensions and two dimensions. Results. The SVNs had a mean diameter of 38.97 nm. The encapsulation and drug-loading efficiencies were and , respectively. In vitro, SVNs and SV can inhibit the proliferation activity and promote osteogenic differentiation of MG63 cells by arresting MG63 cells at the G0/G1 phase without increasing the apoptosis rate. In vivo quantitative results showed that the bone mineral density (BMD), bone volume (BV)/total volume (TV) ratio, and trabecular number (Tb.N) in the gelatin sponge with SVNs (SVNs-GS) group and gelatin sponge with SV (SV-GS) group were 362.1%, 292.0%; 181.3%, 158.0%; and 215.2%, 181.8% of those in the blank control (BC) group, respectively. Histological results identified the new bone tissue in each group as irregular fibrous bone, and the arrangement of trabecular bone was disordered. There were significantly more osteoblasts and new capillaries around the trabecular bone in the SVNs-GS group and SV-GS group than in both the BC and drug-free nanomicelle (DFNs) groups. Both in vitro and in vivo, SVNs exhibited greater osteogenic efficacy than SV. Conclusion. SVNs significantly improved the osteogenic efficacy of SV.
Trauma, infection, and tumors can all cause bone defects. Due to mineral deposits and an insufficient blood supply in bone defect areas, the rate of new bone formation is very slow, and large bone defects cannot self-heal [1, 2]. Methods such as bone grafting, bone tissue engineering, and membrane-guided bone regeneration are commonly used to promote bone defect repair, and the materials used include autogenic bone, allogenic bone, synthetic bone replacement materials, stem cells, and exogenous growth factors [3, 4]. Among these materials, autogenic bone is the gold standard of bone repair materials due to its superior osteoconduction, osteoinduction, and osteogenesis [5]. However, autogenic bone grafting is associated with considerable trauma and increased patient suffering, which substantially limits its clinical application [6]. Allogenic bone, which is mainly derived from human cadavers derived, has been applied in clinical practice and has yielded good results [7]. However, the potential risks of spreading viruses and immunological rejection limit the application of allogenic bone in clinical practice [8]. Synthetic biodegradable bone replacement materials overcome the limitations of the above two materials but have the disadvantages of fast degradation, low strength, and localized inflammation caused by degraded products [9, 10]. The addition of exogenous osteogenic growth factors (such as bone morphogenetic protein 2 (BMP-2)) to the above materials can significantly improve the osteoinductive ability and promote the proliferation and differentiation of osteoblasts [11–14]. However, exogenous osteogenic growth factors are expensive, have a short half-life, are difficult to store, and have low cell-targeting properties [15]. Therefore, some scholars have attempted to identify specific drugs to accelerate the formation of new bone in the bone defect area by regulating endogenous osteogenic growth factors.
Simvastatin (SV), which is commonly used in clinical practice, is inexpensive, safe, and reliable. SV can specifically bind to HMG-CoA reductase, a key enzyme in cholesterol synthesis, to inhibit cholesterol synthesis and prevent cardiovascular diseases [16]. In 1999, Mundy et al. first reported that subcutaneous injection of SV and lovastatin could significantly promote the formation of new bone in a mouse cranial bone defect area [17]. Studies have shown that SV can promote osteogenesis mainly through the induction of BMP-2 and VEGF gene expression, thereby promoting angiogenesis and the differentiation of osteoblasts [17, 18]. In addition, SV inhibits the RANKL expression to suppress the differentiation of osteoclasts and promote osteogenesis [19, 20]. The osteogenesis-promoting effect of SV is closely associated with the regulatory functions of osteogenesis-related signaling pathways, such as the Smad pathway, the Erk1/2 pathway, and the Pi3k/Akt pathway [21–26].
SV is liposoluble and poorly soluble in water. When used systemically, most drugs are metabolized by the liver. Only small amounts of drugs can reach bone defect areas. An extremely low available drug concentration seriously impacts the promoting effect of SV [27]. Increasing the dose of SV for systemic administration can effectively increase the drug concentration in the bone defect area, but high doses can also increase the systemic side effects of SV, such as liver and kidney damage and rhabdomyolysis [28, 29]. Therefore, the extremely low bioavailability in bone defect areas and the potential side effects of SV are urgent problems requiring resolution.
Nano-based drug carriers include nanoparticles, nanoliposomes, solid lipid nanoparticles, magnetic nanoparticles, and polymeric nanomicelles. Among these carriers, polymeric nanomicelles, which were first proposed by Ringsdorf et al. to be used as a drug carrier, have become a research focus of drug delivery systems. Amphiphilic polymeric nanomicelles are self-assembled nanostructures formed by hydrophilic shells and a hydrophobic core. Polymeric nanomicelles are mostly spherical in shape and are mainly used for encapsulation and delivery of lipophilic small-molecule drugs [30, 31]. The particle sizes of polymeric nanomicelles are relatively small, mostly ranging between 10 and 80 nm [32]. Currently, polyethylene glycol (PEG), polyethylene oxide (PEO), and chitosan (CTS) are commonly used in the synthesis of the hydrophilic segments of polymeric nanomicelles [33, 34]. PEG has good water solubility and a large exclusion volume, which can effectively prevent aggregation of micelles. PEG can also reduce the capture of the reticuloendothelial system (RES) and extend the half-life of polymeric nanomicelles [33, 34]. The hydrophobic segments of polymeric nanomicelles are usually synthesized using polylactic acid (PLA) and polycaprolactone (PCL), which mainly serve the functions of encapsulating hydrophobic drugs [30, 34]. Polymeric nanomicelles prepared with these materials have excellent biocompatibility and biodegradability [35]. Polymeric nanomicelles can be excreted through the kidneys and will not accumulate in the body. Therefore, polymer micelles have great application prospects as drug carriers.
We hypothesized that the encapsulation of SV using polymer nanomicelles can significantly improve the in vitro and in vivo osteogenic effect of SV. In previous studies, we applied methoxy-PEG (mPEG-) PLA to encapsulate SV, successfully synthesized simvastatin-loaded nanomicelles (SVNs) by dialysis, and preliminarily verified that an appropriate concentration of SVNs can significantly improve the osteoblast differentiation-promoting effect of SV in vitro [24]. In the present study, we not only further verified the role of SVNs in promoting osteoblast differentiation in vitro but also evaluated the in vivo osteogenesis-promoting effects of SVNs.
2.1. Preparation and Characterization of SVNs
Based on previous experience in preparing nanomicelles in our group [24], SVNs (mPEG-PLA-SV) were prepared using a dialysis method. In short, 10 mg of mPEG-PLA () (Jinan Daigang Biomaterial Co., Ltd., Shandong, China) and 2 mg of SV (National Institutes for Food and Drug Control, Beijing, China) were dissolved in 2 ml of acetonitrile (Fisher Scientific, Waltham, MA, USA) and slowly added dropwise into 12 ml of purified water. The mixture was stirred for 1 h at room temperature and then dispersed via ultrasonication for 5 min. Finally, the above solution was dialyzed for 7 h. The drug-free nanomicelles (DFNs) were also prepared in a similar way in the absence of SV.
The particle sizes of SVNs and DFNs were measured using a Zetasizer instrument (Mastersizer 2000, Malvern Instruments Ltd., Malvern, UK). Nanomicelle morphology was observed with a transmission electron microscope (TEM; HT7700, Hitachi Limited, Tokyo, Japan). High-performance liquid chromatography (HPLC; LC-20AD, Shimazu Corporation, Kyoto, Japan) was used to determine the drug-loading content and drug entrapment efficiency.
2.1.1. In Vitro Simvastatin Release
SVNs were sealed in a dialysis bag and incubated in 4% HAS solution at 37°C and 50 rpm. The same amount of free SV was dialyzed under the same conditions as a control. At predetermined time intervals, 12 ml of the samples was withdrawn and replaced with 12 ml of fresh release medium. The SV concentration was analyzed using the HPLC system.
2.2. Cell Experiment
2.2.1. Cell Culture and Experimental Group
The human osteoblast-like MG63 cells were purchased from the Cell Bank of the Chinese Academy of Sciences, Shanghai, People's Republic of China. The MG63 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin-streptomycin (HyClone, Logan, UT, USA) at 37°C in a humidified incubator with 5% CO2. The medium was refreshed every three days.
The experiment was divided into four groups: SVNs group, SV group as the positive control, DFNs group, and blank control (BC) group as the negative control. According to the preliminary results of our group, the SV in the SVNs group and in the SV group was dissolved and diluted to 0.25 μmol/l in the complete medium. Equal concentrations of DFNs were also prepared.
2.2.2. Cell Proliferation
MG63 cells were seeded onto 24-well plates at 104 cells per well and cultured with the drug formulations (500 μl/well) for 72 h. Then, culture medium was replaced with serum-free medium. The plate was incubated for 2 h at 37°C in a humidified atmosphere with 5% CO2. An MTS assay kit (MTS; Biovision Inc., CA, USA) was used to measure cell proliferation. One hundred microliters of MTS solution was mixed with culture medium per well. One hundred microliters of the mixture was pipetted into each well of a 96-well plate, and absorbance was measured at 30 min intervals at 490 nm using a microplate reader (Tecan, Tecan Trading AG, Switzerland).
2.2.3. Cell Cycle and Apoptosis
MG63 cells were seeded in 6 cm Petri dishes at . The experiment was terminated at 72 h after dosing, and the effects of drugs on the cell cycle and apoptosis of MG63 cells were measured by flow cytometry.
(1) Cell Cycle. A cell cycle detection kit (keygen, Keygen biotech, Jiangsu, China) was used to detect the cell cycle. The cells were digested and collected by centrifugation at 1,000 × g at 4°C for 5 min. With the supernatant removed, the cells were resuspended with 1 ml of precooled Buffer A and collected by centrifugation again. Then, the cells were resuspended with 100 μl of precooled Buffer A, slowly dripped into 900 μl of precooled 70% ethanol, and fixed at -20°C for at least 12 h. The cells were collected by centrifugation again, washed with precooled Buffer A to remove ethanol, and resuspended in 500 μl of Buffer A; then, RNase A was added, and the solution was further incubated at 37°C for 30 min. The samples were stained with propidium iodide (PI) at room temperature for 30 min in the dark and analyzed by flow cytometry.
(2) Cell Apoptosis. An Annexin V-FITC/PI Apoptosis Detection Kit (BD, Becton, Dickinson and Company, NJ, USA) was used to detect the apoptotic cells. The cells were collected using trypsin without EDTA by centrifugation and resuspended with 300 μl 1× binding buffer. One hundred microliters of cell suspension was pipetted into culture tubes; then, 5 μl of Annexin V-FITC was added to each tube, followed by incubation for 15 min at room temperature. Five microliters of PI stain was added to the cells for 5 min at room temperature without light. After the addition of 400 μl of 1× binding buffer to each tube, cell apoptosis was analyzed by flow cytometry.
2.2.4. Alkaline Phosphatase (ALP) Activity
MG63 cells were seeded onto 24-well plates at 104 cells/well. After 7 d of culturing, the culture medium was removed, and 50 μl/well of Laemmli sample buffer together with protease inhibitor (50 : 1 v/v) was added to lyse the cells. Then, the samples were centrifuged at 10,000 rpm, at 4°C. Ten microliters of supernatant was pipetted to measure the protein concentration using a bicinchoninic acid protein assay kit (Thermo, Thermo Fisher Scientific, MA, USA). The absorbance of the solution was measured at 562 nm, and the amount of total protein was calculated using a generated calibration curve. In addition, 30 μl of supernatant was pipetted to measure the ALP activity, and the absorbance of the solution at 520 nm was measured. To determine the ALP activity, the amount of ALP was normalized to the amount of total proteins synthesized.
2.2.5. ALP Staining
The slides of MG63 cells were stained for the presence of ALP using an ALP assay kit (86C-1KT; Sigma-Aldrich Corp., St. Louis, USA) according to the manufacturer's instructions after incubating in various experimental media for 7 d. The cells were fixed in a citrate-acetone-formaldehyde solution for 30 s and then incubated in an ALP mixture solution containing sodium nitrite solution, fast blue BB base (FBB-) alkaline solution, and naphthol AS-BI alkaline solution as a substrate for 30 min at room temperature away from light. Stained cells were rinsed twice with deionized water and photographed.
2.2.6. Western Blotting
MG63 cells were seeded onto 6-well plates at cells/well and cultured with the corresponding drugs according to the experimental group. The protein expression levels of osterix (OSX) and osteocalcin (OC) were determined by western blot analysis according to the following steps: cultured cells were washed twice with ice-cold PBS, and then, the total proteins were extracted from the cells using the RIPA lysis buffer containing a protease inhibitor (Cell Signaling, Cell Signaling Technology Inc., MA, USA) and phosphatase inhibitors (Cell Signaling, Cell Signaling Technology Inc., MA, USA). The protein concentrations were determined using the bicinchoninic acid (BCA) protein assay (Pierce BCA Protein Assay Kit; Thermo Fisher Scientific). An equal amount of protein (20 μg/lane) was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After blocking with 5% BSA in TBS with Tween-20 (TBST) for 60 min, the PVDF membranes were incubated with primary antibodies at 4°C overnight. Next, the membranes were incubated for 60 min at room temperature with a horseradish peroxidase-linked secondary antibody. The bands were visualized using the enhanced chemiluminescence (ECL) detection system. The quantification of protein was calculated by densitometry analysis using the ImageJ software. The primary antibodies used were specific for OSX (1 : 1500 diluted; Abcam, Cambridge, UK), OC (1 : 1500 diluted; Abcam), and GAPDH (1 : 1500 diluted; Cell Signaling, Cell Signaling Technology Inc., MA, USA).
2.3. Animal Experiment
Six New Zealand white rabbits (20–24 weeks, 2.3–0.3 kg) were used as experimental animals in this experiment. The experimental protocol was approved by the Animal Ethics Committee at Shenzhen University.
2.3.1. Surgical Procedure
All surgical procedures were performed under sterile conditions. First, the animals were anesthetized with an injection of 3% sodium pentobarbital (30 mg/kg) into the lateral ear vein. Then, the head of the rabbit was shaved and sterilized with iodine solution. Next, 2 ml of 2% lidocaine was administered to the operating site as local anesthesia. A perpendicular incision was made, and a mucoperiosteal flap was raised. Four critical bone defects (6.5 mm in diameter) were created at the top of the skull and randomly divided into the following four groups: no augmentation (blank control, BC) group, gelatin sponge (GS) group, gelatin sponge with 0.5 mg SV (SV-GS) group, and gelatin sponge with 5 mg SVNs (0.5 mg SV) (SVNs-GS) group. The surgical procedure is depicted in Figure 1. The animals were sacrificed four weeks after surgery.
The surgical procedures with rabbit calvaria. (a) A mucoperiosteal flap was raised, and four critical bone defects (6.5 mm in diameter) were created at the top of the skull. (b) The defects were divided into the following four groups: no augmentation (blank control, BC) group, gelatin sponge (GS) group, gelatin sponge with 0.5 mg SV (SV-GS) group, and gelatin sponge with 5 mg SVNs (0.5 mg SV) (SVNs-GS) group.
2.3.2. Microcomputed Tomography (Micro-CT) Analysis
The effects of SVNs and SV on osteogenesis were evaluated radiographically. The specimens were removed en bloc, fixed in 10% neutral formalin, and scanned with a micro-CT scanner (Skyscan-1176; Bruker, Belgium) (pixel size: 18.05 μm; source voltage: 62 kV; source current: 380 μA). Micro-CT images were reconstructed using Skyscan NRecon software (Bruker, Belgium). The bone defect area (6.5 mm in diameter) of each image was defined as the region of interest (ROI), and the volume of interest (VOI) was made up of the ROIs of 150 images. The newly formed bone volume (BV), bone mineral density (BMD), percent bone volume (bone volume/tissue volume, BV/TV), and trabecular number (Tb.N) of the newly formed bone were measured using Skyscan CTAn software (Bruker, Belgium).
2.3.3. Histomorphometric Analysis
After the specimens were completely fixed, they were demineralized with 10% EDTA for four weeks and paraffin-embedded after dehydration. All the specimens were sectioned into 4 μm-thick serial sections for hematoxylin and eosin (HE) and Masson's trichrome staining for observation of the newly formed bone under a microscope.
2.4. Statistical Analysis
Statistical analysis was performed using SPSS version 19.0 (IBM Corp., Armonk, NY, USA). All data are shown as the (SD) from at least three independent experiments and were analyzed by repeated-measures ANOVA and Student's -test.
3.1. Characterization of Simvastatin-Loaded Nanomicelles
The mean diameter of the SVNs was determined with dynamic light scattering (DLS) and found to be approximately (Figure 2(a)). The SVNs were nearly spherical in shape based on the TEM results (Figure 2(b)). Under 20% theoretical drug-loading capacity (DLC) conditions, the SVNs presented an encapsulation ratio and drug-loading efficiency of and , respectively. These nanomicelles were selected for subsequent experiments to evaluate their osteogenic effects.
The characteristics of simvastatin-loaded nanomicelles. (a) The particle size of simvastatin-loaded nanomicelles was measured using a Zetasizer instrument. (b) Simvastatin-loaded nanomicelle morphology was observed with a transmission electron microscope (TEM). (c) The in vitro cumulative release profiles of simvastatin from simvastatin-loaded nanomicelles using human serum albumin as dissolution medium by a dynamic dialysis method. The simvastatin concentration was measured via the HPLC method at a UV absorbance of 238 nm. The results are the mean values of three independent measurements (±SD).
As shown in Figure 2(c), the free SV was nearly completely released at 12 h, whereas only approximately 35% of the total SV had been released from the nanomicelles at the same time. SVNs showed good sustained-release properties in vitro.
3.2. Cell Experiment Results
Figure 3(a) shows that the number of cells significantly decreased in the SVNs group and the SV group at 3 d after administration of the drugs in comparison with the BC group. The SVNs group had fewest cells, indicating that SVNs exerted a significantly more potent inhibitory effect on cell proliferation than SV.
The effect of SVNs and SV on the proliferative activity of MG63 cells. The results are the mean values of three independent measurements (±SD). vs. BC group; vs. SV group.
3.2.2. Cell Cycle and Cell Apoptosis
To clarify whether the inhibitory effect of SVNs and SV on the proliferative activity of MG63 cells is related to a drug-induced alteration of cell cycle and apoptotic rate, flow cytometry was used to analyze the cell cycle and apoptotic rate of the MG63 cells in all experimental groups.
Figure 4 shows that the percentages of the MG63 cells in the G0/G1 phases of the cell cycle were significantly increased, while the percentage of cells in the S phase of the cell cycle was markedly reduced, in the SVNs group and the SV group 3 d after administration of the drugs in comparison with the BC group. No significant changes were observed in the percentages of G2/M phase cells.
The effect of SVNs and SV on the cell cycle of MG63 cells. The results are the mean values of three independent measurements (±SD). vs. BC group; vs. SV group.
Moreover, Figure 5 shows that the apoptotic rate of MG63 cells did not increase significantly after treatment with SVNs and SV. The above cell proliferation experiment results show that SVNs and SV significantly reduced the number of MG63 cells. The decrease in the number of cells in the SVNs group and the SV group did not appear to be related to apoptosis.
The effect of SVNs and SV on the apoptotic rate of MG63 cells. The results are the mean values of three independent measurements (±SD). vs. BC group; vs. SV group.
3.2.3. ALP Activity Assay
The osteoblastic differentiation of MG63 cells was evaluated by measuring the ALP activity after culturing with different drug formulations for 7 d. As shown in Figure 6(a), the ALP activities of cells in the SVNs group and SV group were significantly higher than those of cells in the BC group, and the SVNs group exhibited the greatest cellular ALP activity. ALP staining results (Figure 6(b)) showed obvious blue areas in the SVNs group and SV group, especially in the SVNs group, and almost no blue areas were observed in the DFN group and BC group. These results are consistent with those of the quantitative analysis of ALP activity described above.
The effect of SVNs and SV on the osteogenic differentiation of MG63 cells. (a) ALP activity was measured in whole-cell extracts. (b) ALP staining. The ALP activity was proportional to the intensity of the blue-violet color. (c) The protein expression of OSX after treatment with different drug formulations for 7 d. (d) The protein expression of OC after treatment with different drug formulations for 14 d. The results are the mean values of three independent measurements (±SD). vs. BC group; vs. SV group.
3.2.4. Protein Levels of OSX and OC
The protein expression levels of OSX and OC in MG63 cells were determined by the western blot analysis. At 7 d or 14 d after drug application, the protein expression levels of OSX (Figure 6(c)) and OC (Figure 6(d)) of cells in the SVNs group and SV group were significantly higher than those of the cells in the BC group. SVNs could further significantly enhance the promoting effect of SV on the expression of OSX or OC in MG63 cells.
The above results showed that SVNs and SV significantly promoted the osteogenic differentiation ability of the MG63 cells in vitro. Their osteogenesis-promoting effect in vivo requires further verification in animal experiments.
3.3. Animal Experiment Results
The animal experiment was executed smoothly, the experimental animals healed well after surgery, and no complications such as inflammation, infection, splitting, or exposure were noted in the surgical area. During specimen preparation, one specimen was damaged and was not included in the subsequent analysis. The number of samples in each group was .
3.3.1. Microcomputed Tomography (CT) Analysis Results
Animals were sacrificed by air injection into an ear vein 4 weeks after surgery. Under sterile conditions, the surgical area was completely delineated at the site larger than 5 mm along the edge of the defect area. After scanning with micro-CT, the Skyscan CTAn software of the scanner was used to perform three-dimensional reconstruction of the defect area (Figure 7(a)). At 4 weeks after surgery, each experimental group had different degrees of new bone formation, and the direction of the new bone formation mainly extended from the edge of the bone defect toward the center of the defect area. New bone formation was most extensive in the SVNs-GS group, followed by the SV-GS group, while new bone formation was the least obvious in the BC group, and large defects were still present in the bone defect area. The bone defect area was further divided into VOI, and three-dimensional reconstructed images more clearly showed that the new bone formation in the SVNs-GS group was significantly more obvious than that in the other groups (Figure 7(b)). Quantitative analysis of BMD (Figure 7(c)), BV/TV ratio (Figure 7(d)), and Tb.N (Figure 7(e)) in the new bone by Skyscan CTAn software showed that the BMDs in the SVNs-GS, SV-GS, and GS groups were 362.1%, 292.0%, and 183.5% of the BMD in the BC group; the BV/TV ratios were 181.3%, 158.0%, and 133.8% of the BV/TV ratio in the BC group; and the Tb.N values were 215.2%, 181.8%, and 145.4% of the Tb.N in the BC group, respectively.
Evaluation of new bone formation in the surgical defect area with micro-CT scanning at 4 weeks after surgery. (a) Three-dimensional reconstruction of the defect area. (b) Three-dimensional reconstruction of VOI. Quantitative analysis of BMD (c), BV/TV ratio (d), and Tb.N (e) in the new bone. The results are the mean values of five independent measurements (±SD). vs. BC group; vs. SV group.
3.3.2. Histological Evaluation Results
At 4 weeks after surgery, sagittal primary bone slices obtained from the centers of the bone defect areas were subjected to HE staining (Figure 8). The results showed that the bone defect areas of each group were covered by new fibrous tissue and immature bone tissue, with a small amount of irregular cancellous bone at the edge of the primary bone defect. The SVNs-GS group had the most newly formed irregular cancellous bone and the smallest remaining bone defect areas. The new bone formation in the SVNs-GS group and SV-GS group was significantly greater than that in the BC group and GS group. Under high magnification, the new bone tissue in each group was identified as irregular fibrous bone, and the arrangement of trabecular bone was disordered; a large number of spindle-shaped osteoblasts were attached to the surface of the primary trabecular bone, and some osteoblasts had transformed into immature bone cells and were buried in the bone lacunae. The extensive new capillary formation was evident around the primary trabecular bone, especially in the SVNs-GS group.
Histologic images of the surgical defects at four weeks (HE stain, ×40, ×100, ×400). The "←" arrows point to the original defect margins, the "↓" arrows indicate newly formed capillary, and the "↑" arrows indicate osteoblasts.
Adjacent blank sections were subjected to Masson trichrome staining (Figure 9). The results showed that the new fibrous tissues in the bone defect areas of all groups were stained blue, the new bone tissue at the edge of the bone defect area was stained blue or red and blue, and the surrounding old bone was stained red. In the BC and GS groups, the arrangement of collagen fibers in the new fibrosis tissues, which showed lighter staining, was sparse and slightly disordered; only a small amount of new bone formation was noted on the edge of the defect, the bone defect area was large, trabecular bone was scarce, and no obvious mature red lamellar bone tissue was observed. In the SVNs-GS and SV-GS groups, the arrangement of collagen fibers in the new fibrosis tissues, which showed darker staining, was regular and dense; a large number of blue or red-blue primary trabecular bones had formed at the edge of the defect area and extended to the center of the defect area, the bone defect area was significantly reduced, and the trabecular bones at the proximal end of the bone defect appeared to be almost mature and exhibited red-stained lamellar bone. These observations were especially obvious in the SVNs-GS group. Under high magnification, the SVNs-GS group and SV-GS group had a large amount of osteoblasts with blue-violet nuclei attached to new trabecular bones that were gradually surrounded by newly formed osteoid, which were buried inside a new trabecular bone to form lacunae, and osteoblasts had gradually transformed into bone cells. The BC and GS groups had formed few new trabecular bones, osteoblasts were mainly located in the newly formed collagen fibers, and no apparent mature bone tissue structure was noted.
Histologic images of the surgical defects at four weeks (Masson stain, ×40, ×100, ×400). The "←" arrows indicate osteoblasts.
Autogenic bone, allogeneic bone, and artificial bone replacement materials are often used in the repair of large bone defects [3–7]. Adding exogenous osteogenic growth factors such as BMP-2 to these materials can increase the osteoinductivity of the materials, thereby enhancing the osteogenesis-promoting effect [11–14]. However, the high cost and short half-life of exogenous osteogenic growth factors largely limit their clinical application [15]. SV, a commonly used lipid-lowering agent, has been found to increase the expression of BMP-2 in osteoblasts in vivo to promote the formation of new bone in bone defect areas [28, 36]. Therefore, SV is expected to replace exogenous BMP-2 for bone formation promotion since the cost of SV is 16,000-times lower than that of BMP-2 [17].
The local concentration of SV in the treatment area is closely related to whether SV can exert its osteogenesis-promoting effect. In animal experiments, SV is mainly administered systemically, and oral administration is the most common route of administration [28]. SV is a lipid-soluble drug with a low affinity for bone. After oral administration, most drugs will be metabolized by the liver, and eventually, only very small amounts of drugs can reach the treatment area [27]. The low concentration of SV in the treatment area results in a negligible promoting effect on new bone formation. Increasing the oral dose and repeated drug administration can enhance the osteogenic effect of SV. However, an excessive dose also substantially increases the likelihood of systemic side effects [28, 29]. Local administration of SV is an effective approach to avoid the above problems [28, 37].
Local administration of SV has the advantages of avoiding liver metabolism and improving the bioavailability of SV. Many methods can be used for local SV administration [38–40]. The simplest method is to combine SV directly with bone scaffold materials. The disadvantage of this method is that due to the burst release effect, a large amount of SV can be released from the stent into the blood and be quickly cleared from the body [28]. As a result, SV can act only for a short time, resulting in a limited osteogenic effect. Therefore, the goal of local SV administration should be slow and sustained drug release to the bone defect area to promote bone formation and to effectively improve the bioavailability of SV [40].
In previous studies, some scholars synthesized SV-loaded microspheres or nanospheres and confirmed that SV could be slowly released from the microspheres or nanospheres [41–44]. The present study used mPEG-PLA polymeric nanomicelles to encapsulate SV using the preferred dialysis method developed in a previous study. The prepared SVNs had a small size and a spherical shape, which extended the release time of the same amount of SV from 12 h to over 100 h, reflecting excellent sustained-release properties.
Few studies related to the osteogenesis-promoting effect of SV are available. Existing studies have shown that nano-based drug carriers can significantly improve the osteogenesis-promoting effect of SV in vivo and in vitro [41–44]. Our previous in vitro study preliminarily confirmed these findings [24]. In the present study, we detected the ALP activity and protein expression levels of OSX and OC in MG63 cells and again confirmed that SVNs can significantly improve the osteoblast differentiation-promoting effect of SV in vitro. In previous studies, we found that after adding SVNs and SV, the number of MG63 cells was significantly decreased compared with that in the control group, and cell proliferation activity was inhibited. The premise of cell differentiation is currently believed to be that cells stop proliferation. Whether the reduced number of cells after drug application is the result of cell differentiation or drug-induced apoptosis requires further investigation. The results of the present study showed that SVNs and SV can block MG63 cells in the G0/G1 phase and thus inhibit cell proliferation; however, SVNs and SV did not increase the cell apoptosis rate. These results suggest that the osteoblast differentiation-promoting effects of SVNs and SV are closely related to changes in the osteoblast cell cycle.
We also evaluated the in vivo osteogenic effects of SVNs and SV through a rabbit skull defect model. To avoid the drawbacks of systemic administration, local SV administration was used in the study. Because micro-CT scans of specimens were needed in the later stage to observe and analyze the new bone formation, we loaded SVNs and SV on gelatin sponges, which do not interfere with X-rays. The amount of SV used in the animal experiments had a significant impact on the experimental results. SV at a low concentration cannot promote the formation of new bone, while excessively high doses of SV can trigger inflammation in the bone defect area and affect bone healing [45]. In animal experiments, doses of 0.1 mg to 0.5 mg of SV have been suggested to be suitable [46]. Within this range, the bone healing-promoting effect of SV was directly proportional to the amount of SV used [47, 48]. Therefore, we selected 0.5 mg as the dose of SV in the present study. Micro-CT quantitative analysis results showed that SVNs and SV both significantly promoted the formation of new bone and significantly increased the BMD and the amount of new trabecular bone in the bone defect area. It is well known that the formation of new bone mainly depends on the number of osteoblasts. Histomorphology qualitative results showed that both SVNs and SV significantly increased the number of osteoblasts in the bone defect area. In addition, both SVNs and SV increased the number of new blood vessels in the bone defect area, which may be related to the promotion of the expression of vascular endothelial growth factor by SVNs and SV, thus stimulating the differentiation of endothelial progenitor cells and ultimately stimulating angiogenesis. The increases in the number of osteoblasts and new blood vessels both promoted the formation and maturation of new bones in the bone defect area. The above quantitative and qualitative results showed that compared with the same amount of SV, SVNs had a greater effect on the promotion of new bone formation in the bone defect area, which may be due to the slow and sustained release of SV by SVNs. SVNs continuously and slowly release SV into the bone defect area to maintain a high local concentration while substantially prolonging the duration of SV action, resulting in a stronger osteogenic effect. In addition, due to their small size, nano-based drug carriers have physical and chemical properties (such as surface effects and small-size effects) that traditional materials do not have. Therefore, SVNs and SV may have significantly different effects on cellular uptake, intracellular distribution, and regulation of osteogenesis-related signaling pathways. Compared with SV, SVNs have a stronger osteogenic effect.
This study has certain limitations. This study did not elucidate the possible mechanism through which SVNs significantly improve the in vivo and in vitro osteogenesis-promoting effect of SV. In addition, this study mainly focused on the effects of SVNs and SV on the early stage of osteogenesis, and further studies are needed to investigate their roles in the late stage of osteogenesis. Finally, porous scaffolds play an important role in bone tissue engineering [49]. In the future, we will try to prepare porous scaffolds combined with SVNs in order to achieve better bone defect repair effects.
This study showed that polymeric nanomicelles can be used to encapsulate SV to prepare SVNs. In vitro, SVNs can promote the differentiation of osteoblasts by arresting osteoblasts at the G0/G1 phase and significantly increase the ALP activity and protein expression levels of markers associated with osteogenesis. In vivo, SVNs can promote the formation and mineralization of new bones in bone defect areas by increasing the number of osteoblasts and new blood vessels and accelerating the repair process of bone defects. Therefore, polymeric nanomicelles can be used as SV carriers to enhance the osteogenic effect of SV.
The data used to support the findings of this study are available from the corresponding author upon request.
The authors report no conflicts of interest in this work.
Xianling Feng and Xinxin Yue contributed equally to this article.
This work was supported by grants from the Characteristic Innovation Project of Guangdong Province (No. 2018GKTSCX028), the Medical Science and Technology Research Foundation of Guangdong Province (No. A2018170), and the Innovative Engineering Project of Shenzhen Polytechnic (cxgc2019c0004).
A. A. El-Rashidy, J. A. Roether, L. Harhaus, U. Kneser, and A. R. Boccaccini, "Regenerating bone with bioactive glass scaffolds: a review of in vivo studies in bone defect models," Acta Biomaterialia, vol. 62, pp. 1–28, 2017. View at: Publisher Site | Google Scholar
A. Noori, S. J. Ashrafi, R. Vaez-Ghaemi, A. Hatamian-Zaremi, and T. J. Webster, "A review of fibrin and fibrin composites for bone tissue engineering," International Journal of Nanomedicine, vol. Volume 12, pp. 4937–4961, 2017. View at: Publisher Site | Google Scholar
A. R. Amini, C. T. Laurencin, and S. P. Nukavarapu, "Bone tissue engineering: recent advances and challenges," Critical Reviews in Biomedical Engineering, vol. 40, no. 5, pp. 363–408, 2012. View at: Publisher Site | Google Scholar
Z. P. Du, X. X. Feng, G. X. Cao et al., "The effect of carbon nanotubes on osteogenic functions of adipose-derived mesenchymal stem cells in vitro and bone formation in vivo compared with that of nano-hydroxyapatite and the possible mechanism," Bioactive Materials, vol. 6, no. 2, pp. 333–345, 2021. View at: Publisher Site | Google Scholar
Y. Li, S. K. Chen, L. Li, L. Qin, X. L. Wang, and Y. X. Lai, "Bone defect animal models for testing efficacy of bone substitute biomaterials," Journal of Orthopaedic Translation, vol. 3, no. 3, pp. 95–104, 2015. View at: Publisher Site | Google Scholar
A. Bow, D. E. Anderson, and M. Dhar, "Commercially available bone graft substitutes: the impact of origin and processing on graft functionality," Drug Metabolism Reviews, vol. 51, no. 4, pp. 533–544, 2019. View at: Publisher Site | Google Scholar
D. J. Hall, T. M. Turner, and R. M. Urban, "Healing bone lesion defects using injectable CaSO4 /CaPO4 -TCP bone graft substitute compared to cancellous allograft bone chips in a canine model," Journal of Biomedical Materials Research. Part B, Applied Biomaterials, vol. 107, no. 2, pp. 408–414, 2019. View at: Publisher Site | Google Scholar
A. Kadam, P. W. Millhouse, C. K. Kepler et al., "Bone substitutes and expanders in spine surgery: a review of their fusion efficacies," International Journal of Spine Surgery, vol. 10, p. 33, 2016. View at: Publisher Site | Google Scholar
T. Rolvien, M. Barbeck, S. Wenisch, M. Amling, and M. Krause, "Cellular mechanisms responsible for success and failure of bone substitute materials," International Journal of Molecular Sciences, vol. 19, no. 10, p. 2893, 2018. View at: Publisher Site | Google Scholar
M. Yamada and H. Egusa, "Current bone substitutes for implant dentistry," Journal of Prosthodontic Research, vol. 62, no. 2, pp. 152–161, 2018. View at: Publisher Site | Google Scholar
Z. P. Du, G. X. Cao, K. Li, R. H. Zhang, and X. M. Li, "Nanocomposites for the delivery of bioactive molecules in tissue repair: vital structural features, application mechanisms, updated progress and future perspectives," Journal of Materials Chemistry B, 2020. View at: Publisher Site | Google Scholar
A. Decambron, A. Fournet, M. Bensidhoum et al., "Low-dose BMP-2 and MSC dual delivery onto coral scaffold for critical-size bone defect regeneration in sheep," Journal of Orthopaedic Research, vol. 35, no. 12, pp. 2637–2645, 2017. View at: Publisher Site | Google Scholar
M. Koolen, A. Longoni, J. van der Stok, O. Van der Jagt, D. Gawlitta, and H. Weinans, "Complete regeneration of large bone defects in rats with commercially available fibrin loaded with BMP-2," European Cells & Materials, vol. 38, pp. 94–105, 2019. View at: Publisher Site | Google Scholar
L. Wei, F. Teng, L. Deng et al., "Periodontal regeneration using bone morphogenetic protein 2 incorporated biomimetic calcium phosphate in conjunction with barrier membrane: a pre-clinical study in dogs," Journal of Clinical Periodontology, vol. 46, no. 12, pp. 1254–1263, 2019. View at: Publisher Site | Google Scholar
P. J. Boyne, S. Salina, A. Nakamura, F. Audia, and S. Shabahang, "Bone regeneration using rhBMP-2 induction in hemimandibulectomy type defects of elderly sub-human primates," Cell and Tissue Banking, vol. 7, no. 1, pp. 1–10, 2006. View at: Publisher Site | Google Scholar
J. Lewandowski, M. Sinski, L. Puchalska, B. Symonides, and Z. Gaciong, "Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels," Journal of the American Society of Hypertension, vol. 8, no. 10, pp. 715–723, 2014. View at: Publisher Site | Google Scholar
G. Mundy, R. Garrett, S. Harris et al., "Stimulation of bone formation in vitro and in rodents by statins," Science, vol. 286, no. 5446, pp. 1946–1949, 1999. View at: Publisher Site | Google Scholar
M. Takenaka, K. Hirade, K. Tanabe et al., "Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells," Biochemical and Biophysical Research Communications, vol. 301, no. 1, pp. 198–203, 2003. View at: Publisher Site | Google Scholar
S. N. Raafat, R. M. Amin, M. M. Elmazar, M. M. Khattab, and A. S. El-Khatib, "The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino rats," Bone, vol. 117, pp. 60–69, 2018. View at: Publisher Site | Google Scholar
J. Zhou, X. Gao, S. Huang et al., "Simvastatin improves the jaw bone microstructural defect induced by high cholesterol diet in rats by regulating autophagic flux," BioMed Research International, vol. 2018, Article ID 4147932, 9 pages, 2018. View at: Publisher Site | Google Scholar
M. Yamashita, F. Otsuka, T. Mukai et al., "Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen–activated protein kinase pathway," The Journal of Endocrinology, vol. 196, no. 3, pp. 601–613, 2008. View at: Publisher Site | Google Scholar
A. Neve, A. Corrado, and F. P. Cantatore, "Osteoblast physiology in normal and pathological conditions," Cell and Tissue Research, vol. 343, no. 2, pp. 289–302, 2011. View at: Publisher Site | Google Scholar
A. N. Tsartsalis, C. Dokos, G. D. Kaiafa et al., "Statins, bone formation and osteoporosis: hope or hype?" Hormones (Athens, Greece), vol. 11, no. 2, pp. 126–139, 2012. View at: Publisher Site | Google Scholar
M. Niu, X. Feng, and L. Zhou, "The role of the ERK1/2 pathway in simvastatin-loaded nanomicelles and simvastatin in regulating the osteogenic effect in MG63 cells," International Journal of Nanomedicine, vol. Volume 13, pp. 8165–8178, 2018. View at: Publisher Site | Google Scholar
P. Y. Chen, J. S. Sun, Y. H. Tsuang, M. H. Chen, P. W. Weng, and F. H. Lin, "Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway," Nutrition Research, vol. 30, no. 3, pp. 191–199, 2010. View at: Publisher Site | Google Scholar
N. Ghosh-Choudhury, C. C. Mandal, and G. G. Choudhury, "Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation," The Journal of Biological Chemistry, vol. 282, no. 7, pp. 4983–4993, 2007. View at: Publisher Site | Google Scholar
P. Gazzerro, M. C. Proto, G. Gangemi et al., "Pharmacological actions of statins: a critical appraisal in the management of cancer," Pharmacological Reviews, vol. 64, no. 1, pp. 102–146, 2011. View at: Publisher Site | Google Scholar
A. Moshiri, A. M. Sharifi, and A. Oryan, "Role of simvastatin on fracture healing and osteoporosis: a systematic review on in vivo investigations," Clinical and Experimental Pharmacology & Physiology, vol. 43, no. 7, pp. 659–684, 2016. View at: Publisher Site | Google Scholar
M. Schachter, "Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update," Fundamental & Clinical Pharmacology, vol. 19, no. 1, pp. 117–125, 2005. View at: Publisher Site | Google Scholar
G. G. Walmsley, A. McArdle, R. Tevlin et al., "Nanotechnology in bone tissue engineering," Nanomedicine: Nanotechnology, Biology and Medicine, vol. 11, no. 5, pp. 1253–1263, 2015. View at: Publisher Site | Google Scholar
G. Gaucher, R. H. Marchessault, and J. C. Leroux, "Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes," Journal of Controlled Release, vol. 143, no. 1, pp. 2–12, 2010. View at: Publisher Site | Google Scholar
V. P. Torchilin, "Structure and design of polymeric surfactant-based drug delivery systems," Journal of Controlled Release, vol. 73, no. 2-3, pp. 137–172, 2001. View at: Publisher Site | Google Scholar
H. Danafar, A. Sharafi, M. H. Kheiri, and S. Andalib, "Sulforaphane delivery using mPEG-PCL co-polymer nanoparticles to breast cancer cells," Pharmaceutical Development and Technology, vol. 22, no. 5, pp. 642–651, 2017. View at: Publisher Site | Google Scholar
Z. Karami, S. Sadighian, K. Rostamizadeh, M. Parsa, and S. Rezaee, "Naproxen conjugated mPEG-PCL micelles for dual triggered drug delivery," Materials Science & Engineering. C, Materials for Biological Applications, vol. 61, pp. 665–673, 2016. View at: Publisher Site | Google Scholar
D. T. Pham, A. Chokamonsirikun, V. Phattaravorakarn, and W. Tiyaboonchai, "Polymeric micelles for pulmonary drug delivery: a comprehensive review," Journal of Materials Science, vol. 56, no. 3, pp. 2016–2036, 2021. View at: Publisher Site | Google Scholar
W. L. Yu, T. W. Sun, C. Qi et al., "Enhanced osteogenesis and angiogenesis by mesoporous hydroxyapatite microspheres- derived simvastatin sustained release system for superior bone regeneration," Scientific Reports, vol. 7, no. 1, article 44129, 2017. View at: Publisher Site | Google Scholar
A. Oryan, A. Kamali, and A. Moshiri, "Potential mechanisms and applications of statins on osteogenesis: current modalities, conflicts and future directions," Journal of Controlled Release, vol. 215, pp. 12–24, 2015. View at: Publisher Site | Google Scholar
A. S. Chauhan, A. Maria, and A. Managutti, "Efficacy of simvastatin in bone regeneration after surgical removal of mandibular third molars: a clinical pilot study," Journal of Maxillofacial and Oral Surgery, vol. 14, no. 3, pp. 578–585, 2015. View at: Publisher Site | Google Scholar
A. Gouda, E. Helal, S. Ali, S. Bakry, and S. Yassin, "Maxillary sinus lift using osteoinductive simvastatin combined with β-TCP versus β-TCP - a comparative pilot study to evaluate simvastatin enhanced and accelerated bone formation," Acta Odontologica Scandinavica, vol. 76, no. 1, pp. 39–47, 2018. View at: Publisher Site | Google Scholar
S. Gupta, M. del Fabbro, and J. Chang, "The impact of simvastatin intervention on the healing of bone, soft tissue, and TMJ cartilage in dentistry: a systematic review and meta-analysis," International Journal of Implant Dentistry, vol. 5, no. 1, p. 17, 2019. View at: Publisher Site | Google Scholar
M. L. Ho, Y. C. Fu, Y. H. Wang, C. H. Chen, G. J. Wang, and G. J. Wang, "Combination of calcium sulfate and simvastatin-controlled release microspheres enhances bone repair in critical-sized rat calvarial bone defects," International Journal of Nanomedicine, vol. 10, p. 7231, 2015. View at: Publisher Site | Google Scholar
X. Liu, X. Li, L. Zhou et al., "Effects of simvastatin-loaded polymeric micelles on human osteoblast-like MG-63 cells," Colloids and Surfaces. B, Biointerfaces, vol. 102, pp. 420–427, 2013. View at: Publisher Site | Google Scholar
L. B. Ferreira, V. Bradaschia-Correa, M. M. Moreira, N. D. Marques, and V. E. Arana-Chavez, "Evaluation of bone repair of critical size defects treated with simvastatin-loaded poly(lactic-co-glycolic acid) microspheres in rat calvaria," Journal of Biomaterials Applications, vol. 29, no. 7, pp. 965–976, 2014. View at: Publisher Site | Google Scholar
I. C. Tai, Y. C. Fu, C. K. Wang, J. K. Chang, and M. L. Ho, "Local delivery of controlled-release simvastatin/PLGA/HAp microspheres enhances bone repair," International Journal of Nanomedicine, vol. 8, p. 3895, 2013. View at: Publisher Site | Google Scholar
M. Nyan, T. Miyahara, K. Noritake et al., "Molecular and tissue responses in the healing of rat calvarial defects after local application of simvastatin combined with alpha tricalcium phosphate," Journal of Biomedical Materials Research. Part B, Applied Biomaterials, vol. 9999B, 2009. View at: Publisher Site | Google Scholar
S. Chen, J. Y. Yang, S. Y. Zhang, L. Feng, and J. Ren, "Effects of simvastatin gel on bone regeneration in alveolar defects in miniature pigs," Chinese Medical Journal, vol. 124, p. 3953, 2011. View at: Google Scholar
X. Yue, M. Niu, T. Zhang et al., "In vivo evaluation of a simvastatin-loaded nanostructured lipid carrier for bone tissue regeneration," Nanotechnology, vol. 27, no. 11, article 115708, 2016. View at: Publisher Site | Google Scholar
Y. Lee, M. J. Schmid, D. B. Marx et al., "The effect of local simvastatin delivery strategies on mandibular bone formation in vivo," Biomaterials, vol. 29, no. 12, pp. 1940–1949, 2008. View at: Publisher Site | Google Scholar
K. Zhang, Y. B. Fan, N. Dunne, and X. M. Li, "Effect of microporosity on scaffolds for bone tissue engineering," Regenerative Biomaterials, vol. 5, no. 2, pp. 115–124, 2018. View at: Publisher Site | Google Scholar
Copyright © 2020 Xianling Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This responds to your letter asking about emergency exit labeling requirements in Federal Motor Vehicle Safety Standard (FMVSS) No. 217, Bus emergency exits and window retention and release. You ask which of two labels your client, an urban bus manufacturer, should use on their emergency exit windows.
As required by S5.3.1 of Standard No. 217, two motions are necessary to open the exits of your client=s buses. The first is to pull down on a red latch at the top center of the window. The second is to push to the left a handle at the bottom right of the window. Your first label depicts only the action of pulling down the red latch. Your second label shows the sequence of first pulling down the red latch and then pushing the handle to the left.
You are correct in your assumption that only the second emergency exit label is permitted. The language in S5.5.1 requires the label to have A. . . the designation >Emergency exit= followed by concise operating instructions describing each motion necessary to unlatch and open the exit . . .@ (emphasis added). The word Aeach@ explains that all necessary motions have to be described. The words Aand open@ explicitly include the motion to open the window. The first label only tells how to unlatch the window, not how to open it. The second label tells how to unlatch and open the window.
I hope this information is helpful. If you have any further questions, feel free to contact Paul Atelsek of my staff at 202-366-5260.


All successful design projects require collaboration and open communication between the client and the designer. I have been fortunate enough to have had the opportunity to work with a wide variety of amazing clients in the greater Madison area.
High recommendations for Sarah! Small projects or large. She is easy to work with, willing to help via phone, email or shopping, and hourly rates were clear and reasonable. Well worth the value she brought!
We recently completed a home addition and whole home renovation, and couldn't be happier with how the house turned out! It is always nice to have a trained eye guiding you, and we could not have done it without Sarah.
Our project was the classic HGTV "tear out this wall, tear-out that wall" approach as we took our house from the 80's to a beautiful open-concept that works for our family. We did much of the work ourselves, moving some walls and redefining areas so we could get a larger entryway, mudroom, open kitchen with island, an office, den, etc. Sarah shared ideas online, joined us at vendors, and met at our house many times to pick finishes that work for us and completed the whole design.
Sarah is a great interior designer, but for us that didn't just mean picking out finishes and furniture, it also meant helping us plan the new spaces when it came to moving some walls around. Sarah's ideas were a little different than our original sketches, and I'm glad she got involved then and made her mark on the design. The final result was much improved by her involvement early.
Choosing furniture, floor coverings, paint colors, window coverings, finishes, or designing spaces – we will go to Sarah again. Thanks!
She's easy to communicate with and is very responsive.
Sarah is amazing to work with. She helped us with room layouts and selecting furniture, rugs and accessories for multiple rooms. We couldn't be happier with the results. She took time to understand what we were looking for. She's easy to communicate with and is very responsive. She has been great to work with every step of the way and we look forward to continuing to work with her.
Sarah was the key that resulted in the completion of our remodel...(she) made timely, thoughtful observations and recommendations. I appreciated her no nonsense approach that made the most of her time, as well as my time and budget. I would not hesitate to recommend Sarah and would love to work with her again the next time I need a nudge with a project!
I had the pleasure of working with Sarah on my recent kitchen remodel. I needed help with a few key decisions which kept hanging up my ability to move forward with the project. I am so glad that she was recommended to me. Sarah was the key that resulted in the completion of our remodel.
Sarah walked into my home and made timely, thoughtful observations and recommendations. She followed up with check-in emails that kept me focused and moving forward.
I appreciated her no nonsense approach that made the most of her time, as well as my time and budget. I would not hesitate to recommend Sarah and would love to work with her again the next time I need a nudge with a project!
I wanted to work with a professional designer who would listen to our ideas, work with what we already had, prevent us from making costly mistakes and help us pull together an interior space we could live in happily. Sarah is doing exactly that.
Sarah Helf is the perfect designer for our condo remodeling project. Because we are updating our kitchen and master bathroom, selecting new light fixtures and replacing carpet with vinyl plank flooring, I wanted to work with a professional designer who would listen to our ideas, work with what we already had, prevent us from making costly mistakes and help us pull together an interior space we could live in happily. Sarah is doing exactly that. She responds quickly to questions and meets with us as needed; she understands our style and the space. Sarah bills us for her design work as we need it and is willing to work with us as our time and budget permits.
She is able to understand the look you want and achieve it. We trust her judgement, love her ideas and highly recommend her.
Sarah is wonderful to work with. She is very professional and her ideas are fantastic. She is able to understand the look you want and achieve it. She listens to your ideas, makes suggestions and then gives you her professional opinion why some things may be better than others. She has the insight to see what it will eventually look like when it is done. She has a good eye for color and texture . We love what she has done with our house.
She responds quickly when you need help even when you are out of town and find something that you want her opinion on. She works with your budget and timeline.
The first time my husband met her he commented that he liked how she thought. He commented that she was practical and knowledgable. He's a tech ed. teacher so that says a lot.
We trust her judgment, love her ideas and highly recommend her.
She suggested things I wouldn't have considered myself, but wound up liking very much...She has a great sense for an overall look as well as practical considerations of durability, functionality and creating something you can live in.
Sarah was so helpful when we moved into our new house. We needed to buy furniture for almost every room. Sarah helped us with layouts and created inventories for each room of what we needed to buy. She understood our style and helped us find pieces that worked together and fit our budget. She suggested things I wouldn't have considered myself, but wound up liking very much. When she suggested something I didn't like, she took the feedback and came back with additional options. She has a great sense for an overall look as well as practical considerations of durability, functionality and creating something you can live in. We will continue to work with Sarah as we move on to additional steps in our new house.
She was professional and fun to work with at all times.
I found Sarah through Houzz and couldn't be happier that I did! We wanted to update our living room space to include new furniture and new accessories. We also wanted to change the furniture arrangement to create a more conversational space. New window treatments would complete the look. Sarah did a wonderful job in finding all the right pieces for us to select from. She was professional and fun to work with at all times. The fabricator she works with did a fantastic job on the window treatments. We are very pleased with the results.
Her sense for colors, textures, and fabrics, along with her knowledge of local and web-based vendors at various price points was impressive. My project was on a tight schedule and Sarah was extremely accommodating in providing thoughtful plans and proposals in a timely fashion.
Sarah worked with me on my living room and did a great job. Her sense for colors, textures, and fabrics, along with her knowledge of local and web-based vendors at various price points was impressive. My project was on a tight schedule and Sarah was extremely accommodating in providing thoughtful plans and proposals in a timely fashion. I found Sarah to be really professional and would highly recommend her.
Sarah mixed together the style of our old school house with function. I am proud to have family and friends visit-our old house is the best its been in the 40 years we're lived here. Thank you, Sarah!
Sarah has been wonderful to work with. I live a couple hours away, and one day Sarah combined stopping out for a first hand look with a family gathering this direction. Sarah listens and works within your budget, desires and pieces you'd like to keep. When I sent an email, Sarah responded within hours or less. Sarah mixed together the style of our old school house with function. I am proud to have family and friends visit-our old house is the best its been in the 40 years we're lived here. Thank you, Sarah!
We have been very satisfied with her guidance in choosing electrical and plumbing fixtures, paint colors, flooring, tile selection, furniture arrangement and more! She quickly completes any task while incorporating our suggestions and feedback. I just couldn't be happier to have found such a great designer.
Sarah has been amazing to work with! She quickly understood our design aesthetic and the direction we wanted to go in. She is very efficient with her time, which in turn has saved us an enormous amount of time on our farmhouse remodel/addition. We have been very satisfied with her guidance in choosing electrical and plumbing fixtures, paint colors, flooring, tile selection, furniture arrangement and more! She quickly completes any task while incorporating our suggestions and feedback. I just couldn't be happier to have found such a great designer.
She asked tons of questions at our initial visit, which was great because it was clear she wanted to design our home for us. She offered a more formal design process or a more casual bounce-ideas-back-and-forth approach - whichever we were more comfortable with.
I have thoroughly enjoyed working with Sarah. She is responsive, flexible and has great energy. We hired her to help us with a difficult layout in the living room and included her on plans that we would like to someday complete.
She asked tons of questions at our initial visit, which was great because it was clear she wanted to design our home for us. She offered a more formal design process or a more casual bounce-ideas-back-and-forth approach – whichever we were more comfortable with. We have two preschool boys and she totally excelled at consulting in our sometimes very noisy, interruption-heavy environment.
Even though we didn't have the budget to do everything we would like to eventually tackle, she took our big picture plans into account from day one and helped create a phased strategy that would maximize impact as we have budget to execute. We plan to use Sarah quite a bit in the years that come!
Sarah did a great job of listening to our wishes and needs, and then creating a vision that worked with the architecture, finishes and celebrated the family pieces we wanted to work into the plan...Sarah has a creative mind and remained really flexible as we worked through the process. She's a pleasure to work with, and I'm happy to highly recommend her!
Sarah recently helped us transform the main living space in our home, which includes the living room, dining area and solarium. The home is new to us, has a very unique layout, and is a style that is quite different from our old home…so definitely a challenge to incorporate the pieces we wanted to keep with the new space. Sarah did a great job of listening to our wishes and needs, and then creating a vision that worked with the architecture, finishes and celebrated the family pieces we wanted to work into the plan. Sarah helped us with layout recommendations, furniture, rug and fabric selection and guidance in designing a custom dining room storage piece. Sarah has a creative mind and remained really flexible as we worked through the process. She's a pleasure to work with, and I'm happy to highly recommend her!
She understood our casual style and designed a comfortable yet stylish space. It feels fresh but not too trendy so it will stand the test of time, and we loved how creative she was with inexpensive elements...Working with Sarah is like hanging out with your super stylish friend.
I love working with Sarah! She helped us with a total remodel of our basement family room and my daughter's bedroom.. She understood our casual style and designed a comfortable yet stylish space. It feels fresh but not too trendy so it will stand the test of time, and we loved how creative she was with inexpensive elements.
Working with Sarah is like hanging out with your super stylish friend. She guides you toward things that will work and away from design mistakes without making you feel like a design idiot.
Sarah is always available on email for those last minute decisions I'm just not comfortable making on my own. She comes prepared and is not afraid to tell us her honest opinion.
Sarah has helped us with a large mudroom and kitchen remodel and definitely nailed exactly what we were looking for. From her original designs to the helping us with the final touches, the rooms came out better than we expected.
We hired Sarah again to help us with a bathroom remodel and now that she definitely knows our style and tastes it's going even more smoothly and quickly than the last remodel.
Sarah is always available on email for those last minute decisions I'm just not comfortable making on my own. She comes prepared and is not afraid to tell us her honest opinion.
I feel she is a designer that listens to her clients wishes and guides them professionally through the process.
I first contacted Sarah through Houzz for help with paint color selection in my entire home. She was very professional and asked me questions about what my vision was for the finished "look". She provided a wonderful palette of colors for my home. They turned out beautiful. I have recently called on her again to help me with a room layout and furnishings. I feel she is a designer that listens to her clients wishes and guides them professionally through the process. She also respects any budget you may have.
© 2019 Sarah Helf Interior Design. All Rights Reserved.


text:
Public sector pay policy 2021-2022 (superseded)
Budget and Public Spending Directorate
Economy, Money and tax, Public sector, +1 more … Scottish Budget
This was the original pay policy document as announced on 28 January 2021. Following negotiations during the passage of the draft Budget Bill, a revised pay policy document was issued in March 2021.
Public sector pay
Foreword by the Cabinet Secretary for Finance
Public Sector Pay Policy for 2021-22
Staff Pay Remits
Senior Appointments
No Compulsory Redundancy
Equalities Assessment
The results from the equality impact assessment of the 2021-22 Public Sector Pay Policy are available on the Scottish Government's Public Sector Pay webpages at:
www.gov.scot/publicsectorpay.
The continued progressive approach proposed in the 2021-22 Public Sector Pay Policy helps to reduce overall income inequality. It may also help in positively working towards reducing the gender pay gap within the public sector as it should increase the overall base levels of pay for those at the lower end where women are overly concentrated. This is further supported by the continued restraint applied to higher earners, including senior appointments, where there are higher proportions of men.
The application of the real Living Wage of £9.50 per hour and the £750 cash underpin will positively benefit lower paid staff and in particular those with one or more protected characteristic. From the data available, there is a higher proportion of women, disabled people, individuals from a minority ethnic group, younger employees or a combination of one or more of these protected characteristics as well as part-time workers among lower paid employees. Therefore the measures proposed in the pay policy protect these employees from pay restraint and in many cases provide a positive benefit.
While we are satisfied that the risk of any indirect discrimination, as a result of capping the pay for higher earners, can be justified by the overarching aims of the pay policy, it will still be necessary for individual employers to ensure that they do not introduce or perpetuate any direct or indirect discrimination for individuals in their application of the policy. Employers covered by the pay policy are also subject to the statutory public sector equality duty, and it is their responsibility to ensure their pay systems are fair and non-discriminatory and that they undertake an assessment of their pay proposals prior to submitting them to the Scottish Government.
The pay policy will set the overarching framework within which public bodies can make individual choices on the impact of the policy on their own circumstances. Public bodies have the flexibility to draw up their own pay proposals to take into account local pay issues such as recruitment and retention, equality and the impact of the lower pay measures on other staff. The pay policy actively encourages employers to take into account their own staffing profile, local evidence, views of staff and unions and equality issues in framing their pay proposals.
A Technical Guide providing further detail to assist public bodies in the preparation of their Staff and Senior Appointment pay remit proposals under this policy will be published separately. This will be available on the Scottish Government's Public Sector Pay webpages at: www.gov.scot/publicsectorpay.
Email: FinancePayPolicy@gov.scot

redpajama_set_name: RedPajamaCommonCrawl


In Villa Mala everything functions taking into consideration the friendly and adapted approach for the protection of the environment. Starting with the architecture which is completely harmonized with the environment, the construction materials of the hotel, the insulation and all the saving energy systems we use.
***Cretan products and Cretan cuisine hold an important position in international gastronomy due to their high quality and their beneficial effects on human health. In order to preserve, promote and disseminate this nutritional pattern, the Region of Crete in partnership with the non-for-profit "Cretan Quality Agreement" certifies restaurants with the "Quality Label of Cretan Cuisine".
The aim of Region of Crete is to create a prestige and credibility Pancretan Quality Label, that is practicable, harmonized with modern needs and internationally recognizable, which will be established in the minds of residents and visitors of the island and strengthen the reputation of Cretan diet model. It will also increase the rising demand for the provision of authentic Cretan cuisine and the development of culinary tourism.
Promote the certified restaurants in national and international level.


Syrian passports which are issued for six years in one time only. If the passport is extended after the six years, the consulate cannot extend it.
The consulate does NOT issue new Syrian passports.
يتم تمديد جوازات السفر على ان لايكون الجواز قد تجاوز مدته القانونية وهي ستة سنوات. اذا كان قد تم تمديد الجواز حتى ولو لمره واحده بعد الست سنوات فلايمكن تمديده ويجب الحصول على جواز سفر جديد. القنصليه لاتصدر جوازارت سفر سوريه جديده.
Complete The Application for the Consular Registration Form and follow the consular registration instructions.
Pre-paid airway bills preferably FedEx, to return the passport to you.


text:
Gabardini Monoplane
Tractor Monoplane
Friuli - monoplane - 1913 - Италия <– –> Gabardini - Biplane - 1914 - Италия
The Gabardini type of monoplane took the competent by storm when it first appeared in 1913 to the public.
With two adult passengers and an 80 h.p. rotary engine, the late Philip Cevasco made a non-stop flight from Milan to Venice, and otherwise proved the powers of the machine to be quite exceptional and unusually well suited for all sorts of general conditions.
With a smaller engine, the Gabardini was found to be ideal for training pilots, and so a large school and works were opened at Cameri, in 1914, and were got into swing in time for the work of preparation for war.
Squat and inelegant and built largely of metal, the monoplanes are distinctive, not freakish nor reminiscent of any other aeroplane.
Signor Gabardini, who at one time dedicated himself to art of another sort, is a Piemontese by birth, and cruelly crippled, mental energy alone being in his power of recent years. He has. however, the satisfaction of having produced one of the very few monoplanes which has survived the ban and disfavour into which single-deckers have fallen, and his joy therein is shewn by the pride with which he claims it the best, after trial, in all the world.
The type has had a long testing during four war years of gruelling, with barely a modification, and that in the cockpit, in all that time.
So responsive to control is the Gabardini that its designer states that "they answer the intangible helm of the pilot's intention before the material leverage has come into action."
In flight, the Gabardini reminded one of the Antoinettes, curiously, since the design of the two is so entirely opposite. Up till now radial motor> are fitted, with rotaries for school machines.
With a motor less costly in upkeep, the Gabardini monoplane is a machine which may. one hopes, become a useful means of commercial transport, being a good lander, a weight-earner and stable. A commercial traveller's vehicle possibly ?
The work of training some 300 pilots carried on at Cameri has kept Signor Gabardini's designing energy rather in the background necessarily.
THE GABARDINI MONOPLANE.
Type of machine Tractor Monoplane.
Name or type No. of machine Gabardini.
Purpose for which intended Training Machine.
Span 10 m.
Total surface of wings 18 sq. m.
Engine type and h.p. 50 h.p. Gnome.
Speed low down 100 km.p.h.
Flight, November 6, 1914.
AEROPLANE TYPES.
ONE of the most successful machines which have been produced in Italy is the Gabardini monoplane, many of which have been turned out from the works at Cameri, Novara. Although a first glance at the accompanying sketch plan and elevation gives one the impression that this machine is on Nieuport lines, it really differs from this latter make considerably, notably in the construction of the fuselage. The latter is constructed of steel tube reinforced with wood, forming a strong and light combination. The forward portion is rectangular in section from the nose carrying the engine - an 80 h.p. Gnome - to the rear of the pilot's and passenger's cockpit, where the lower longerons meet. From this point the remainder of the fuselage is of triangular section. This arrangement gives an excellent streamline form, and also allows plenty of room for engine, fuel tanks, control gear, and pilot and passenger. The triangular portion of the fuselage can be detached, thus greatly facilitating transport and housing.
The wings, which have a maximum camber of 190 mm., are built up on two main spars of tubular steel, upon which the ribs are loosely mounted so that they possess a certain amount of free movement when warping takes place. The ribs consist of single one-piece webs with top and bottom flanges. Holes are drilled in the webs of each rib for nearly the whole length, rendering the wing very light and strong. The empannage is somewhat unusual in that it is mounted well in advance of the vertical rudder, so that the latter has a wide range of movement. It consists of a fixed semicircular plane, with two similarly shaped elevator flaps hinged to the trailing edge. The fixed plane, elevators, and rudder are constructed of steel tubing. Lateral control is by wing warping operated by a central lever, which also controls the elevators. The rudder is actuated by pedals. The chassis consists of two skids, upturned in front to protect the propeller, connected to the fuselage by three struts each. A tubular axle carrying a pair of running wheels is mounted on the skids by means of elastic bands. A hydro, model is also made, which differs from the land machine in dimensions and in the attachment of the two floats. The principal dimensions of the land model are as follows :- Span, 9 m.; supporting area, 18 sq. m.; overall length, 7 m.; weight, empty, 350 kgs.; useful load, 350 kgs.; speed, 65-135 k.p.h.
Flight, June 18, 1915.
AN ITALIAN MONOPLANE THE GABARDINI.
OF the several Italian-designed aeroplanes, the Gabardini monoplane, built at Cameri, is perhaps the most interesting and one of the most successful. It was the Gabardini monoplane that was employed for the first civilian aviation school at Cameri, whilst this make of machine has several non-stop flights to its credit, including Milan-Rome, Milan-Turin and Milan-Venice (with three passengers).
The Gabardini monoplane - described in FLIGHT on November 6th last - although resembling somewhat the Nieuport, really differs from this French make considerably. For instance, it is built mostly of steel, whilst the body is peculiar in that from the nose to a point immediately behind the pilot's cockpit it is rectangular in section, after which it is of triangular section. The steel tubes forming the body are reinforced with wood, providing a light but extremely strong combination.
The wings, which have an upturned entering edge, like the Nieuport, are built up on tubular steel spars with wood I-section ribs loosely mounted thereon so that there is a certain amount of free movement for warping. Another interesting feature is the tail planes, consisting of a semi-circular stabilising surface and two similarly shaped elevator flaps, which are mounted on the body some distance from the rudder, so that the latter has a wide range of action. The engine employed is an 80 h.p. Gnome, built in Italy by the Fabbrica Italiana Motori Gnome at Turin.
A Gabardini monoplane with 80 h.p. Italian-built Gnome engine.
Gabardini Monoplame for elementary instruction (35 h.p. Anzani).
Gabardini Monoplame with 50 h.p. Gnome engine.
A Gabardini Monoplame with 80 h.p. Le Rhone engine.
The sheds and machines at the Gabardini aerodrome at Cameri (Novara).
A Gabardini captive monoplane used to teach the use of controls.


As part of the annual budgetary procedure, the Council today adopted its guidelines for the 2020 EU budget.
The guidelines set out the Council's priorities for the preparation of the EU budget for next year. They serve as input for the Commission before it presents its draft budget, which will serve as the basis for negotiations between the Council and the European Parliament.


text:
Now optimized for iPhone and mobile screens!
Posts tagged with "2020 presidential election"
Above, former President Barack Obama. (Photo source: clickondetroit.com)
Poll: Obama's endorsement would substantially sway 2020 Democratic voters
Does the endorsement of a candidate by a former U.S. president matter to Americans who are likely to vote in the 2020 election? Not unless the backing comes from Barack Obama, based on the results of a national poll conducted last week by USA TODAY/Suffolk Poll.
Obama, who left the White House nearly three years ago after completing two terms in office, polled as the top former president whose opinion mattered—with an overwhelming 67%.
The only other past presidential nominee who polled in double-digits was former President Jimmy Carter, the oldest living POTUS at age 95. In fact, 11% of respondents cited Carter—who is still actively building houses and doing other good works—as someone they admired who is still influential.
Former President Bill Clinton and former Secretary of State Hillary Clinton were next in line, at 6% each. Al Gore, the 2000 nominee, was named by 3%; and Michael Dukakis (1988), John Kerry (2004), and Walter Mondale (1984), by 1% each.
Obama has yet to endorse anyone in the Democratic primary field, which includes his former vice president, Joe Biden.
However, Kate Pritchard, 63, a retired teacher from Durango, Colorado, told USA Today that should plans on supporting New Jersey Sen. Cory Booker at the moment, but she's not sure he can go the distance.
If Obama were to endorse a candidate, she said, she would back that person.
"That would be very powerful," she said in a follow-up interview after being called in the survey.
Research contact: @USATODAY
This entry was posted in Politics and tagged 2020 presidential election, Democratic primary field, Former President Barack Obama, Former President Bill Clinton, Former President Jimmy Carter, Former Secretary of State Hillary Clinton, Gas not backed a candidate yet, Joe Biden, Likely voters, Obama endorsement would substantially help candidate win by 67%, USA TODAY/Suffolk University Poll on November 1, 2019 by Poll-Vaulter.
Room at the top? Biden (left), Warren, and Buttigieg are the leading Democratic fundraisers; but not in that order. (Photo source: Flipboard)
'Fortune' may be favoring just a few Democratic candidates
Eleven Democratic presidential candidates—nearly half of the whopping field of two dozen or more who have announced that they are running—spent more campaign cash than they raised during the second quarter of the year, according to new financial disclosures filed July 15 and posted by Politico.
Indeed fortune is smiling on just a favored few—among them, Pete Buttigieg ($24.8 million raised in Q2), Joe Biden ($21.5 million), Elizabeth Warren ($19.1 million), Bernie Sanders ($18.2 million), and Kamala Harris ($12 milion).
In the second tier are, Corey Booker ($4.5 million), Amy Klobuchar ($3.9 million), and Beto O'Rourke (3.6 million).
Eight contenders active in the spring limped forward with less than $1 million in cash on hand, and several top-tier contenders were already spending multiples of what their lower-profile competitors raised, the news outlet reported.
Already, California Representative Eric Swalwell has pulled out—acknowledging the problematic math facing a lower-tier contender. Swalwell's campaign raised just more than $880,000 in the second quarter from donors and, like many of the others at the bottom of the pack, well outspent what it raised.
"We had the money in our account to continue to try to qualify for the upcoming debate," Swalwell told Politico. "But we believed that even if we had done that, that when we looked at the September debate, it just wouldn't add up."
The financial squeeze is set to drastically shrink the lineup of Democratic contenders in the coming months, barring major shifts in momentum, as candidates grapple with the doldrums of summer fundraising and the high costs of staffing national campaigns and building donor lists big enough to qualify for future Democratic National Committee debates, Politico says.
The numbers also reveal the tremendous pressure on lesser-known candidates to make a splash in the debates at the end of this month — potentially the last chance some will have to attract a burst of support as their expenses pile up.
"This is the doomsday scenario for a lot of campaigns, where they're grasping for air to keep their campaigns alive and to live another day," said Andrew Feldman, a Democratic strategist in Washington. "You can't build an organization. You can't build an operation that turns enthusiasm into votes without having resources to do it."
Former Colorado Governor John Hickenlooper spent a half-million dollars more than he raised in the second quarter, finishing June with $840,000 in his campaign account, Politico said.
Former Housing and Urban Development Secretary Julián Castro spent more than 80% of the amount he raised, despite a fundraising bounce following his highly regarded debate performance in the closing days of the fundraising period. He was left with about $1.1 million, the politico news outlet noted.
Jay Inslee, the governor of Washington, raised about $3.1 million in the second fundraising quarter; however, he reported spending $3.2 million and finished with only $1.2 million in the bank.
"Some of these candidates need a miracle," Matthew Littman, a Democratic strategist and former Joe Biden speechwriter who now supports Kamala Harris, told Politico. "It's like if you're a baseball team and you're 15 games behind in mid-July, the odds are that you're not making it to the playoffs."
He said, "If you don't have the money, you're not going to have the infrastructure. And if you don't have the money or the infrastructure, what are you going to do to break through? At this point, it's just very, very tough."
Could there be a miracle? It's doubtful. "You're not going to see a lot of people continuing to give to a person with no money left," Feldman said.
Research contact: @politico
This entry was posted in Politics and tagged 2020 presidential election, Bernie Sanders, Chances are not good for others, Debates, Democratic candidates, Democratic strategists Andrew Feldman and Matthew Littman, Elizabeh Warren, Eric Swalwell already pulled out, Fundraising leaders, Joe Biden, Others spent more than they raised, Pete Buttigieg, Politico, Presidential candidates on July 16, 2019 by Poll-Vaulter.
Connecticut Governor Dannel Malloy has committed to sign the bill. (Photo source: Official photo)
Connecticut commits Electoral College votes to winner of 2020 popular election
Connecticut's legislature has passed a bill that would give the state's seven Electoral College votes to the presidential candidate who wins the popular vote nationally in 2020.
The state Senate voted 21-14 on May 5 to join the National Popular Vote Interstate Compact, which already included 10 states and the District of Columbia. The state House passed the measure (HB5421) last week, 77 to 73.
Until Connecticut joined, the National Popular Vote possessed 165 electoral votes—61% of the 270 electoral votes necessary to activate it, including:
Four small jurisdictions (Rhode Island, Vermont, Hawaii and the District of Columbia);
Three medium-size states (Maryland, Massachusetts and Washington); and
Four big states (California, Illinois, New Jersey and New York).
In Connecticut, the bill next moves to the Governor's desk—and Governor Dannel P. Malloy (D) already has said that he means to sign it.
"With the exception of the presidency, every elected office in the country, from city council, to United States senator, to governor, is awarded the candidate who receives the most votes," Governor Malloy said, adding, "The vote of every American citizen should count equally, yet under the current system, voters from sparsely populated states are awarded significantly more power than those from states like Connecticut. This is fundamentally unfair. The National Popular Vote compact will ensure an equal vote for every American citizen, regardless of which state they happen to live in. I applaud the General Assembly for passing this commonsense legislation."
"Voting is a foundation of democracy, a fundamental responsibility, and one of the highest forms of civic engagement," Lt. Governor Nancy Wyman said. "From young people going to the polls for the first time to residents who never miss a chance to cast a ballot, citizens must trust that they have a voice in choosing their president. This legislation is a step in that direction and I commend the legislature for sending it to the Governor's desk."
Research contact: @GovMalloyOffice
This entry was posted in Politics and tagged 2020 presidential election, Connecticut joins movement, Give electoral votes to winner of popular vote, Governor Dannel Malloy to sign bill, HB5421, Lt. Goveernor Nancy Wyman, National Popular Vote Interstate Compact, Seven electoral votes on May 7, 2018 by Poll-Vaulter.
© 2020 Poll-Vaulter. All Rights Reserved.
For information: info@poll-vaulter.com
To contact the editor: cheryl@poll-vaulter.com
For media only: media@poll-vaulter.com